BNF:

13.6.3

Status:

Red

Decision Date:

May 2014

Comments

Indicated for the symptomatic treatment of facial erythema of rosacea in adults where quality of life is severely impaired by the rosacea, and alternative treatments are not suitable.

Red Drug Classifications

• 1: Requiring specialist assessment to enable patient selection, initiation and ongoing treating
• 2: Requiring long term on-going monitoring of efficacy by a specialist and not suitable for shared care
• 3: Requiring long term on-going monitoring of toxicity by a specialist (either because of difficulty in recognising side effects or high cost of investigations to identify toxicity)
• 5: Is new to clinical practice and unfamiliar, necessitating a period of accumulation of experience, firstly (and most rapidly) by consultants/specialists

search again